PubMed:32542212
Annnotations
LitCovid-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 6-13 | CHEBI:24505 | denotes | heparin |
T2 | 6-13 | CHEBI:24505 | denotes | heparin |
T3 | 14-23 | CHEBI:36357 | denotes | molecules |
T4 | 14-23 | CHEBI:36357 | denotes | molecules |
T5 | 50-61 | NCBITaxon:11118 | denotes | coronavirus |
T6 | 76-84 | SP_7 | denotes | COVID-19 |
T7 | 199-203 | CHEBI:23888 | denotes | drug |
T8 | 199-203 | CHEBI:23888 | denotes | drug |
T9 | 321-335 | CHEBI:52217 | denotes | pharmaceutical |
T10 | 321-335 | CHEBI:52217 | denotes | pharmaceutical |
T11 | 407-414 | CHEBI:24505 | denotes | heparin |
T12 | 407-414 | CHEBI:24505 | denotes | heparin |
T13 | 457-468 | NCBITaxon:11118 | denotes | coronavirus |
T14 | 474-486 | GO:0050817 | denotes | coagulopathy |
T15 | 533-540 | CHEBI:24505 | denotes | heparin |
T16 | 533-540 | CHEBI:24505 | denotes | heparin |
T17 | 545-553 | SP_7 | denotes | COVID-19 |
T18 | 566-575 | GO:0043335 | denotes | unfolding |
T19 | 616-623 | CHEBI:24505 | denotes | heparin |
T20 | 616-623 | CHEBI:24505 | denotes | heparin |
T21 | 629-638 | CHEBI:36357 | denotes | molecules |
T22 | 629-638 | CHEBI:36357 | denotes | molecules |
T23 | 691-738 | SP_7 | denotes | severe acute respiratory syndrome coronavirus 2 |
T24 | 704-715 | UBERON:0001004 | denotes | respiratory |
T25 | 740-750 | SP_7 | denotes | SARS-CoV-2 |
T26 | 844-851 | CHEBI:24505 | denotes | heparin |
T27 | 844-851 | CHEBI:24505 | denotes | heparin |
T28 | 880-890 | SP_7 | denotes | SARS-CoV-2 |
T29 | 963-973 | SP_7 | denotes | SARS-CoV-2 |
T30 | 1001-1008 | CHEBI:24505 | denotes | heparin |
T31 | 1001-1008 | CHEBI:24505 | denotes | heparin |
T32 | 1009-1018 | CHEBI:36357 | denotes | molecules |
T33 | 1009-1018 | CHEBI:36357 | denotes | molecules |
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 6-13 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T2 | 6-13 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T3 | 407-414 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T4 | 407-414 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T5 | 533-540 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T6 | 533-540 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T7 | 616-623 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T8 | 616-623 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T9 | 844-851 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T10 | 844-851 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T11 | 1001-1008 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T12 | 1001-1008 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 6-13 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T2 | 407-414 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T3 | 533-540 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T4 | 616-623 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T5 | 844-851 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T6 | 1001-1008 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 34-44 | Disease | denotes | COVID-2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 50-74 | Disease | denotes | coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 76-84 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 228-237 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T5 | 474-486 | Disease | denotes | coagulopathy | http://purl.obolibrary.org/obo/MONDO_0001531 |
T6 | 545-553 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 691-738 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T8 | 691-724 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T9 | 740-748 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T10 | 752-761 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T11 | 880-888 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T12 | 891-900 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T13 | 963-971 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T14 | 974-983 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 653-654 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 926-927 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 1045-1046 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 6-13 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T2 | 14-23 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
T3 | 199-203 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T4 | 321-335 | Chemical | denotes | pharmaceutical | http://purl.obolibrary.org/obo/CHEBI_52217 |
T5 | 407-414 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T6 | 533-540 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T7 | 616-623 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T8 | 629-638 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
T9 | 844-851 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T10 | 1001-1008 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T11 | 1009-1018 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 474-486 | Phenotype | denotes | coagulopathy | http://purl.obolibrary.org/obo/HP_0003256 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-45 | Sentence | denotes | Using heparin molecules to manage COVID-2019. |
T2 | 46-172 | Sentence | denotes | The coronavirus disease 2019 (COVID-19) pandemic is becoming one of the largest global public health crises in modern history. |
T3 | 173-345 | Sentence | denotes | The race for an effective drug to prevent or treat the infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. |
T4 | 346-487 | Sentence | denotes | Recent evidence reports that the use of low-molecular-weight heparin reduces mortality in patients with severe coronavirus with coagulopathy. |
T5 | 488-762 | Sentence | denotes | Although the full scope of the benefits from heparin for COVID-19 patients is unfolding, encouraging clinical data suggest that heparin-like molecules may represent a useful approach to treat or prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. |
T6 | 763-901 | Sentence | denotes | The intent of this article is to offer our opinions on the mechanism(s) by which heparin may attenuate the course of SARS-CoV-2 infection. |
T7 | 902-1074 | Sentence | denotes | Furthermore, we propose a novel strategy to treat or prevent SARS-CoV-2 infection using "designer" heparin molecules that are fabricated using a synthetic biology approach. |